Tempus, University of Michigan partner for personalized cancer care

University of Michigan Comprehensive Cancer Center and the health-tech company Tempus have partnered to bring the personalized MI-ONCOSEQ platform to cancer patients across the country.

The platform will sequence germline and tumor DNA to assist physician recommendations of clinical trials or targeted therapies, based on the molecular profile of each patient. MI-ONCOSEQ was developed at the University of Michigan to leverage gene sequencing techniques for cancer patients — in particular, patients for whom either there is no standard of care for their disease or for whom the standard of care has proven ineffective. The platform will integrate Tempus' software and analytic tools, which provide clinical decision support for physicians.

"'A 'one-size-fits-all' approach is not effective in managing cancer," said Arul Chinnaiyan, MD, PhD, director of the Michigan Center for Translational Pathology. "We hope to make it commonplace for patients to have a molecular blueprint of their tumor and for their physicians to have access to innovative clinical research and analytic tools that will provide evidence for their decision making."

More articles on health IT:
Anthem's Medicare Advantage in New Hampshire to cover telehealth services
Johns Hopkins Medicine, JHU Applied Physics Laboratory leverage systems engineering for healthcare
Global spending on medical device security to triple by 2021: 5 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months